Repository logo
 
Publication

The Effectiveness of Therapeutic Vaccines for the Treatment of Cervical Intraepithelial Neoplasia 3: A Systematic Review and Meta-Analysis

2022-09-19Journal article Open access
Simple item page
dc.contributor.authorVentura, Cathy
dc.contributor.authorLuís, Ângelo
dc.contributor.authorSoares, Christiane P.
dc.contributor.authorVenuti, Aldo
dc.contributor.authorPaolini, Francesca
dc.contributor.authorPereira, L.
dc.contributor.authorSousa, Ângela
dc.date.accessioned2022-12-28T09:51:28Z
dc.date.available2022-12-28T09:51:28Z
dc.date.issued2022-09-19
dc.description.abstractCervical cancer (CC) is a disease that affects many women worldwide, especially in low-income countries. The human papilloma virus (HPV) is the main causative agent of this disease, with the E6 and E7 oncoproteins being responsible for the development and maintenance of transformed status. In addition, HPV is also responsible for the appearance of cervical intraepithelial neoplasia (CIN), a pre-neoplastic condition burdened by very high costs for its screening and therapy. So far, only prophylactic vaccines have been approved by regulatory agencies as a means of CC prevention. However, these vaccines cannot treat HPV-positive women. A search was conducted in several databases (PubMed, Scopus, Web of Science, and ClinicalTrials.gov) to systematically identify clinical trials involving therapeutic vaccines against CIN 3. Histopathological regression data, immunological parameters, safety, DNA clearance, and vaccine efficacy were considered from each selected study, and from the 102 articles found, 8 were selected based on the defined inclusion criteria. Histopathological regression from CIN 3 to CIN < 1 was 22.1% (95% CI: 0.627–0.967; p-value = 0.024), showing a vaccine efficacy of 23.6% (95% CI; 0.666–0.876; p-value < 0.001). DNA clearance was assessed, and the risk of persistent HPV DNA was 23.2% (95% CI: 0.667–0.885; p-value < 0.001). Regarding immunological parameters, immune responses by specific T-HPV cells were more likely in vaccinated women (95% CI: 1.245–9.162; p-value = 0.017). In short, these studies favored the vaccine group over the placebo group. This work indicated that therapeutic vaccines are efficient in the treatment of CIN 3, even after accounting for publication bias.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.doi10.3390/vaccines10091560pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.6/12545
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.relationHealth Sciences Research Centre
dc.relationHealth Sciences Research Centre
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectCervical cancerpt_PT
dc.subjectClinical trialspt_PT
dc.subjectMeta-analysispt_PT
dc.subjectSystematic reviewpt_PT
dc.subjectTherapeutics vaccinespt_PT
dc.titleThe Effectiveness of Therapeutic Vaccines for the Treatment of Cervical Intraepithelial Neoplasia 3: A Systematic Review and Meta-Analysispt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleHealth Sciences Research Centre
oaire.awardTitleHealth Sciences Research Centre
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDP%2F00709%2F2020/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F00709%2F2020/PT
oaire.citation.issue9pt_PT
oaire.citation.startPage1560pt_PT
oaire.citation.titleVaccinespt_PT
oaire.citation.volume10pt_PT
oaire.fundingStream6817 - DCRRNI ID
oaire.fundingStream6817 - DCRRNI ID
person.familyNameVentura
person.familyNameSantos Luís
person.familyNameVenuti
person.familyNamePaolini
person.familyNamePereira
person.familyNameSousa
person.givenNameCathy
person.givenNameÂngelo Filipe
person.givenNameAldo
person.givenNameFrancesca
person.givenNameLuísa
person.givenNameÂngela
person.identifier817754
person.identifier.ciencia-id591B-139C-CB73
person.identifier.ciencia-id3D14-798B-65D3
person.identifier.ciencia-id5C1C-AEE3-389B
person.identifier.ciencia-id0F19-FB2C-A7CE
person.identifier.ciencia-id4F15-1868-D001
person.identifier.ciencia-idFB1F-08DE-23FE
person.identifier.orcid0000-0003-0712-6522
person.identifier.orcid0000-0003-2322-6857
person.identifier.orcid0000-0002-7384-6248
person.identifier.orcid0000-0002-9068-4607
person.identifier.orcid0000-0001-9155-7581
person.identifier.scopus-author-id10839238300
person.identifier.scopus-author-id24330268800
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationba625953-f217-4a87-8f82-a748ba5ababf
relation.isAuthorOfPublicationa2d7c872-99db-41e1-9bc9-82c2d47b4661
relation.isAuthorOfPublicationff286fbe-13dd-4bba-a334-634f106246cd
relation.isAuthorOfPublicationf9222003-d8d1-48c0-98e0-702262e36bdd
relation.isAuthorOfPublication604e508e-9f4e-4950-b2a4-1b06c7192afe
relation.isAuthorOfPublicationd77f9086-cf6f-47c2-b06b-072d926f77b2
relation.isAuthorOfPublication.latestForDiscoveryba625953-f217-4a87-8f82-a748ba5ababf
relation.isProjectOfPublicationa4dfaeb8-2685-4a99-ba26-acc4e4a3d7c5
relation.isProjectOfPublicationc7cee677-067c-47b2-ab19-b2dd5b0fda9d
relation.isProjectOfPublication.latestForDiscoveryc7cee677-067c-47b2-ab19-b2dd5b0fda9d

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
vaccines-10-01560.pdf
Size:
2.8 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ICI - C4 | Centro de Competências em Cloud Computing | Documentos por Auto-Depósito
FCS - DCM | Documentos por Auto-Depósito
ICI - CMA | Documentos por Auto-Depósito